Loading provider…
Loading provider…
Medical Oncology Physician in San Francisco, CA
NPI: 1417911751Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get M.D. Mark's Phone Numberphone_androidMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2004 - 2027
NY State Medical License
1989 - 2005

American Board of Internal Medicine
Medical Oncology
Tufts University School Of Medicine
medicine.tufts.edu
Medical School
Until 1988
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
1991 - 1996
New York Presbyterian Hospital (Cornell Campus)
Residency • Internal Medicine
1988 - 1991
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 49 | 78 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 21 | 113 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 16 | 16 |
Authors: Larry Norton, Clifford Hudis, Gabriella D'Andrea, Shanu Modi, Diana Lake
Journal: Clin Breast Cancer
Authors: Laura Esserman, Michelle Melisko, Amy Chien, Wolfgang Korn, Hope Rugo, Emmett Schmidt, Andrew Ko
Journal: Breast Cancer Res Treat
Publication Date: 2016-02-13
Lead Sponsor: University of California, San Francisco
Collaborators: Eisai Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Eribulin
Lead Sponsor: University of California, San Francisco
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: lapatinib ditosylate, GENETIC: gene expression analysis, OTHER: diagnostic laboratory biomarker analysis
Lead Sponsor: University of California, San Francisco
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: paclitaxel, DRUG: lapatinib